Company: CERO
Filing Date: 2025-02-07
Form Type: 424B3
Source: 0001213900-25-011071
Chunk: 279

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-02-07
Form: 424B3
Chunk 279
---
 has served                                                                                                           
 as the Chairman and Chief Executive Officer since December 2024, and previously served as (i) interim Chairman and Chief Executive 
 Officer from October 2024 to November 2024, (ii) Vice Chairman of the board of directors from February 2024 to September 2024, and 
 (iii) the Chief Executive Officer of PBAX until the closing of the Business Combination in February 2024.                          |

| (5) | Phoenix Biotech Sponsor,                                                                             
 LLC beneficially owned more than 5% of our outstanding capital stock at the time of the transaction. |

Policies and Procedures for Related Party Transactions

We have adopted a code of
conduct and ethics requiring us to avoid, wherever possible, all conflicts of interests, except under guidelines or resolutions approved
by the board of directors (or the appropriate committee of the board of directors) or as disclosed in public filings with the SEC. Under
the adopted code of conduct and ethics, conflict of interest situations include any financial transaction, arrangement or relationship
(including any indebtedness or guarantee of indebtedness) involving us.

In addition, pursuant to
the Audit Committee charter, our Audit Committee is responsible for reviewing and approving related party transactions to the extent
that we entered into such transactions. An affirmative vote of a majority of the members of the Audit Committee present at a meeting
at which a quorum is present will be required in order to approve a related party transaction. Without a meeting, the unanimous written
consent of all of the members of the Audit Committee will be required to approve a related party transaction. We also require each of
our directors and officers to complete a directors’ and officers’ questionnaire that elicits information about related party
transactions. These procedures are intended to determine whether any such related party transaction impairs the independence of a director
or presents a conflict of interest on the part of a director, employee or officer.

Our Audit Committee reviews
on a quarterly basis all payments that were made to the officers or directors, or to their affiliates.

<div align='center'>164

DESCRIPTION OF SECURITIES</div>

General

We are authorized to issue
up to 1,000,000,000 shares of Common Stock, and 10,000,000 shares of Preferred Stock.

Preferred Stock

Our Board is authorized
to issue “blank check” Preferred Stock, which may be issued in one or more series upon the authorization of the Board. The
Board is authorized to fix the designations,